Skip to main content
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES — Investor Relations & Filings

Ticker · ABT ISIN · US0028241000 LEI · HQD377W2YR662HK5JX27 US Manufacturing
Open in API
Filings indexed 4,256 across all filing types
Latest filing 2015-12-04 Regulatory Filings
Country US United States of America
Listing US ABT

About ABBOTT LABORATORIES

https://www.abbott.com

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of life-changing technologies. The company's operations are focused on four core businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The Medical Devices division offers solutions for cardiovascular health, diabetes care (including the FreeStyle Libre continuous glucose monitoring system), and neuromodulation. The Diagnostics segment provides a wide range of in vitro diagnostic systems and tests for hospitals, laboratories, and clinics. The Nutrition business develops and markets science-based nutritional products for people of all ages, with leading brands such as Similac, PediaSure, Ensure, and Glucerna. The Established Pharmaceuticals division provides a portfolio of branded generic medicines to consumers in emerging markets.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 30, 2015, by Abbott Laboratories. The content describes a notice regarding a temporary suspension of trading under the company's employee benefit plans due to administrative changes, including changing recordkeepers and trustees. It includes a notice sent to directors and executive officers about blackout trading restrictions. There are no financial statements, earnings data, or detailed management discussion. The document is a regulatory announcement about trading restrictions and administrative changes, typical of a regulatory filing rather than a financial report or management report. It also includes a notice to insiders about trading restrictions, which is not a director's dealing report but a compliance notification. The document length is 4656 characters, which is relatively short and consistent with a regulatory filing. Therefore, the best classification is Regulatory Filings (RNS).
2015-12-04 English
Abbott Laboratories Form 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 30, 2015, by Abbott Laboratories. It reports a temporary suspension of trading under the company's employee benefit plans due to administrative changes causing a blackout period. The document includes a notice to directors and executive officers about trading restrictions during this blackout period, referencing Sarbanes-Oxley Act and Regulation BTR. The content is regulatory in nature, reporting a specific event affecting insider trading restrictions and employee plans, but it does not contain financial statements, earnings data, or detailed management discussion. It is not an annual or quarterly report, nor an earnings release or proxy statement. It is a current report on Form 8-K, which is a regulatory filing used to announce material events. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (6748 characters) and content confirm it is a full filing, not just a brief announcement or certification.
2015-12-04 English
10-Q
Interim / Quarterly Report 9M 2015
2015-11-05 English
Abbott Laboratories 3rd Quarter Form 10Q
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-Q' and is described as a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the quarterly period ended September 30, 2015. It contains detailed financial statements including condensed consolidated statements of earnings, comprehensive income, balance sheet, cash flows, and notes, as well as management's discussion and analysis. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. These characteristics match the definition of an Interim / Quarterly Report (IR). Q3 2015
2015-11-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 21, 2015, by Abbott Laboratories. It specifically reports the results of operations for the third quarter of 2015. The text mentions that the results are announced via a press release (Exhibit 99.1) and includes non-GAAP financial measures. The document is relatively short (4051 characters) and primarily serves as a current report announcing quarterly financial results rather than containing the full financial statements or detailed analysis. This matches the description of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. It is not a full Interim/Quarterly Report (IR) because it does not contain comprehensive financial statements or substantive financial data and analysis, but rather a summary announcement. Therefore, the correct classification is ER with high confidence.
2015-10-21 English
Abbott Laboratories Form 8-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 21, 2015, by Abbott Laboratories. It announces the company's third-quarter 2015 financial results, including detailed sales figures, earnings per share, and segment performance. The document includes a press release with operational and reported sales data, EPS guidance, and business segment commentary. The presence of detailed financial data and analysis for a quarterly period, including actual financial statements and management commentary, indicates this is a comprehensive interim financial report. The Form 8-K is used here to report quarterly earnings results, which aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an earnings release (ER) because it contains detailed financial data and segment analysis beyond key highlights. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive financial content rather than just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2015
2015-10-21 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.